ReviewFrontiers in immunology2026
Evaluating antioxidant treatment approaches for eosinophilic chronic sinusitis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis with eosinophilia (ECRS) is a refractory sinusitis characterized by eosinophilia in the nasal mucosa and peripheral blood. In ECRS, multiple nasal polyps are present in the ethmoid sinuses, and the disease is often accompanied by olfactory dysfunction and asthma. It is a disease that significantly impairs the quality of life of patients by causing persistent nasal congestion and thick nasal discharge, leading to decreased concentration and insomnia. From previous studies, we found that (1) defects in Cu,Zn-SOD in ECRS epithelium contribute to increased IL-17A, macrophage infiltration in the subepithelial tissue, and excessive production of mucin gene (MUC5AC) in the epithelium, thereby potentially exacerbating inflammation and excessive mucus secretion, and (2) reduced HO-1 expression in the epithelium and macrophage infiltration are associated with epithelial damage in CRS accompanied by eosinophil infiltration. These findings suggest that antioxidants may play a crucial role in elucidating the pathophysiology of refractory diseases such as ECRS and may provide new therapeutic strategies. In this paper, three new comprehensive molecular signaling pathway networks of (1) oxidative stress, (2) inflammation inhibition mechanisms and (3) inflammation in ECRS were developed for the first time, based on a critical analysis of scientific literature. In addition, three immunology flowsheets related to oxidative stress, inflammation and carbon monoxide-based inflammation inhibition mechanisms of ECRS were developed for the first time and examined from both clinical and biochemical perspectives. Based on these pathways, this study identified the treatment targets which can be used in future ECRS treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.